Author

Ugo De Giorgi

Istituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriORCID 0000-0001-7520-2908Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Abdullah AltuleaiD· 1 shared Abel Soto-GameziD· 1 shared Alessandro VanniniiD· 1 shared Alessia Marinelli· 1 shared Angela Maria MartinelliiD· 1 shared Ariadna Camacho Martinez· 1 shared Boshi WangiD· 1 shared Caterina GianniiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdullah AltuleaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 7, 2026

The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals

Federico Vannuccini, Yari Ciani, Vera Mugoni…·Francesca Demichelis

The paper profiles EV-RNA and cfDNA from mCRPC patients to identify prognostic biomarkers and tumor microenvironment signals.

DOI 10.64898/2026.09.03.747025

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyThe EMBO JournalPeer-reviewedFeb 10, 2025

Pharmacological CDK4/6 inhibitors promote senescence-associated lysosomal alterations and enhance sensitivity to lysosomotropic agents in breast cancer

Jamil Nehme, Sjors Maassen, Sara Bravaccini…·Marco Demaria

This study shows CDK4/6 inhibitors induce senescence-like changes in breast cancer cells, increasing their sensitivity to lysosomotropic agents, and suggests sequential treatment could improve therapy efficacy.

19 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky